Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Growth Metrics

MedWellAI (MWAI) Asset Writedowns and Impairment (2018 - 2025)

MedWellAI has reported Asset Writedowns and Impairment over the past 4 years, most recently at $648715.0 for Q2 2025.

Quarterly Asset Writedowns and Impairment changed N/A to $648715.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $752125.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $752125.0 for FY2025, N/A changed from the prior year.
Asset Writedowns and Impairment was $648715.0 for Q2 2025 at MedWellAI, up from $103410.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $648715.0 in Q2 2025 and troughed at $103410.0 in Q3 2024.